Long-term survival in patients with advanced non –small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study

Atezolizumab (anti –programmed death-ligand 1 [PD-L1]) received approval from the US Food and Drug Administration and European Medicines Agency for previously treated advanced non–small-cell lung cancer based on OAK—a randomised, phase III trial that showed significantly improved survival with atezolizumab versu s docetaxel regardless of PD-L1 expression. With longer follow-up, we summarised the characteristics of long-term survivors (LTSs).

Source: European Journal of Cancer - December 15, 2018 Category: Cancer & Oncology Authors: J. von Pawel, R. Bordoni, M. Satouchi, L. Fehrenbacher, M. Cobo, J.Y. Han, T. Hida, D. Moro-Sibilot, P. Conkling, D.R. Gandara, A. Rittmeyer, M. Gandhi, W. Yu, C. Matheny, H. Patel, A. Sandler, M. Ballinger, M. Kowanetz, K. Park Tags: Original Research Source Type: research